FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2571123047> ?p ?o ?g. }

• W2571123047 abstract "Abstract Abstract 4564 Background Granulocyte colony-stimulating factor (G-CSF) stimulates the proliferation and differentiation of hematopoietic stem and progenitor cells. Recombinant human G-CSF (filgrastim) was developed by Amgen to enhance mobilization of peripheral blood progenitor cells (PBPCs) prior to autologous or allogeneic hematopoietic stem/progenitor cell transplantation. After the patent expiry of Amgen filgrastim (Neupogen®), Hospira developed a biosimilar filgrastim. Preclinical and phase I studies supported the bioequivalence of Hospira filgrastim and Amgen filgrastim in terms of their physicochemical, pharmacokinetic and pharmacodynamic characteristics (Skrlin A, et al. EHA 2009, Abstract 0568; Waller CF, et al. EHA 2009, Abstract 0562). Here we compare the impact of Hospira filgrastim and Amgen filgrastim on CD34+ PBPC mobilization in a randomized, double-blind phase I study. Aim To demonstrate the bioequivalence of Hospira filgrastim and Amgen filgrastim with respect to the mobilization of CD34+ PBPCs. Methods Healthy, male or female volunteers aged 18–50 years were enrolled at Charles River Clinical Services, Edinburgh, UK, between 2 November 2006 and 24 January 2007. Using a computer-generated randomization list, volunteers were first randomized to 5μg/kg or 10μg/kg dose groups, before further randomization to order of agent administration. Subcutaneous injections of Hospira filgrastim or Amgen filgrastim were administered under double-blind conditions on five consecutive days (days 1–5), with crossover to the alternative agent after a washout period of ≥13 days. Blood samples were taken at day 1 (pre dose), day 3 (6 hours [h] post dose), day 5 (6 h post dose), day 7 (48 h post dose) and day 10 (120 h post dose). Mean CD34+ cell counts were evaluated by flow cytometry and bioequivalence was assessed using a mixed effects analysis of variance model. Bioequivalence was concluded if the 90% confidence intervals (CI) for the ratio of ‘test’ (Hospira filgrastim) to ‘reference’ (Amgen filgrastim) mean CD34+ cell counts at day 5 were completely within the conventional bioequivalence limits of 0.80–1.25. Results Twenty-four volunteers were randomized to the 5μg/kg group and 26 to the 10μg/kg group. At both doses, CD34+ cell counts were similar with Hospira filgrastim and Amgen filgrastim across all time points. Regardless of agent or dose, mean CD34+ cell count at day 1 was 2.2–2.8 cells/μl, increasing to a maximum count at day 5. In the 5μg/kg group, mean CD34+ cell count at day 5 (n=24) was 47.2 cells/μl (95% CI: 36.1, 61.7) with Hospira filgrastim and 46.0 cells/μl (95% CI: 33.6, 63.0) with Amgen filgrastim. In the 10μg/kg group, mean CD34+ cell count at day 5 (n=23) was 81.9 cells/μl (95% CI: 64.5, 104.0) with Hospira filgrastim and 77.5 cells/μl (95% CI: 59.4, 101.3) with Amgen filgrastim (Figure 1). At both doses, 90% CIs for the ratios of test to reference mean CD34+ cell counts at day 5 were within the predefined range required to demonstrate bioequivalence. The incidence of adverse events (AEs) was slightly lower with Hospira filgrastim than with Amgen filgrastim at both doses (5μg/kg, 79 vs 83%; 10μg/kg, 77 vs 92%). The most frequently reported AEs of any severity (mild/moderate/severe) with each agent at each dose were back pain (38–62%) and headache (44–58%), which could be treated with standard analgesics. Conclusions Hospira filgrastim and Amgen filgrastim are similar in their ability to stimulate mobilization of CD34+ PBPCs. These data add to a growing body of evidence in support of the bioequivalence of these agents. Hospira filgrastim may provide a useful alternative to Amgen filgrastim as a growth factor to support PBPC mobilization and transplantation. The bioequivalence of these agents may enable Hospira filgrastim to be used without the need to adapt PBPC harvesting protocols. The continued clinical development of Hospira filgrastim is warranted. Acknowledgments Medical writing support provided by Hannah FitzGibbon (GeoMed) with financial support from Hospira. Disclosures: Bronchud: Hospira UK Ltd: Consultancy. Waller:Hospira UK Ltd: Consultancy. Off Label Use: Hospira filgrastim is a biosimilar filgrastim that is in clinical development for the treatment of neutropenia associated with cytotoxic chemotherapy.. Mair:Charles River Clinical Services: Employment. Challand:Hospira UK Ltd: Employment." @default.
• W2571123047 created "2017-01-13" @default.
• W2571123047 creator A5023538410 @default.
• W2571123047 creator A5043349793 @default.
• W2571123047 creator A5051558775 @default.
• W2571123047 creator A5056354952 @default.
• W2571123047 date "2009-11-20" @default.
• W2571123047 modified "2023-09-27" @default.
• W2571123047 title "BIOEQUIVALENCE of a BIOSIMILAR FILGRASTIM and REFERENCE FILGRASTIM: IMPACT ON the MOBILIZATION of CD34+ PERIPHERAL BLOOD PROGENITOR CELLS in a RANDOMIZED, PHASE I STUDY." @default.
• W2571123047 doi "https://doi.org/10.1182/blood.v114.22.4564.4564" @default.
• W2571123047 hasPublicationYear "2009" @default.
• W2571123047 type Work @default.
• W2571123047 sameAs 2571123047 @default.
• W2571123047 citedByCount "1" @default.
• W2571123047 crossrefType "journal-article" @default.
• W2571123047 hasAuthorship W2571123047A5023538410 @default.
• W2571123047 hasAuthorship W2571123047A5043349793 @default.
• W2571123047 hasAuthorship W2571123047A5051558775 @default.
• W2571123047 hasAuthorship W2571123047A5056354952 @default.
• W2571123047 hasConcept C112705442 @default.
• W2571123047 hasConcept C126322002 @default.
• W2571123047 hasConcept C201750760 @default.
• W2571123047 hasConcept C204243189 @default.
• W2571123047 hasConcept C2776694085 @default.
• W2571123047 hasConcept C2777767877 @default.
• W2571123047 hasConcept C2779171977 @default.
• W2571123047 hasConcept C28328180 @default.
• W2571123047 hasConcept C42404028 @default.
• W2571123047 hasConcept C535046627 @default.
• W2571123047 hasConcept C54355233 @default.
• W2571123047 hasConcept C59491497 @default.
• W2571123047 hasConcept C71924100 @default.
• W2571123047 hasConcept C86803240 @default.
• W2571123047 hasConcept C98274493 @default.
• W2571123047 hasConceptScore W2571123047C112705442 @default.
• W2571123047 hasConceptScore W2571123047C126322002 @default.
• W2571123047 hasConceptScore W2571123047C201750760 @default.
• W2571123047 hasConceptScore W2571123047C204243189 @default.
• W2571123047 hasConceptScore W2571123047C2776694085 @default.
• W2571123047 hasConceptScore W2571123047C2777767877 @default.
• W2571123047 hasConceptScore W2571123047C2779171977 @default.
• W2571123047 hasConceptScore W2571123047C28328180 @default.
• W2571123047 hasConceptScore W2571123047C42404028 @default.
• W2571123047 hasConceptScore W2571123047C535046627 @default.
• W2571123047 hasConceptScore W2571123047C54355233 @default.
• W2571123047 hasConceptScore W2571123047C59491497 @default.
• W2571123047 hasConceptScore W2571123047C71924100 @default.
• W2571123047 hasConceptScore W2571123047C86803240 @default.
• W2571123047 hasConceptScore W2571123047C98274493 @default.
• W2571123047 hasLocation W25711230471 @default.
• W2571123047 hasOpenAccess W2571123047 @default.
• W2571123047 hasPrimaryLocation W25711230471 @default.
• W2571123047 hasRelatedWork W179710147 @default.
• W2571123047 hasRelatedWork W1975739282 @default.
• W2571123047 hasRelatedWork W2084472832 @default.
• W2571123047 hasRelatedWork W2136859014 @default.
• W2571123047 hasRelatedWork W2154836716 @default.
• W2571123047 hasRelatedWork W2241579338 @default.
• W2571123047 hasRelatedWork W2499295470 @default.
• W2571123047 hasRelatedWork W2534956500 @default.
• W2571123047 hasRelatedWork W2559911792 @default.
• W2571123047 hasRelatedWork W2563401391 @default.
• W2571123047 hasRelatedWork W2586537389 @default.
• W2571123047 hasRelatedWork W2588633943 @default.
• W2571123047 hasRelatedWork W2660387909 @default.
• W2571123047 hasRelatedWork W2743213847 @default.
• W2571123047 hasRelatedWork W2743347613 @default.
• W2571123047 hasRelatedWork W2771295128 @default.
• W2571123047 hasRelatedWork W2912694021 @default.
• W2571123047 hasRelatedWork W2989777472 @default.
• W2571123047 hasRelatedWork W3198253307 @default.
• W2571123047 hasRelatedWork W37935334 @default.
• W2571123047 isParatext "false" @default.
• W2571123047 isRetracted "false" @default.
• W2571123047 magId "2571123047" @default.
• W2571123047 workType "article" @default.